​Gordon B. Mills, MD, PhD, says individualized treatment, as opposed to treating patients solely based on their malignancy type, must happen in order to improve patient outcome.
Gordon B. Mills, MD, PhD
Advertisement
Articles by Gordon B. Mills, MD, PhD
Gordon B. Mills, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses assay of the genome in order to further measure DNA and RNA.
Advertisement
Latest Updated Articles
Dr. Mills Discusses Assay of the Genome to Further Measure DNA and RNAPublished: August 27th 2015 | Updated:
Dr. Gordon B. Mills on Moving Toward Patient-Specific Treatment in Breast CancerPublished: December 30th 2015 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
